Zero Breast Cancer at CHE’s Post

🧬 Unlock the Future of Cancer Research: Clonal Hematopoiesis and Cancer Genetics 🧬 Curious about the latest breakthroughs in cancer genetics? Join Dr. Karina Eterovic, MSc, PhD, NYS CoQ, R&D Director at Eurofins Viracor BioPharma Services, as she unravels the intriguing link between clonal hematopoiesis and cancer. 🔍 Key insights include: - How blood cells expand from a single clone due to somatic mutations - The rising prevalence of clonal hematopoiesis with age - Differentiating clonal hematopoiesis from tumor-specific mutations These findings are reshaping cancer diagnostics and treatment strategies. 📖 Dive into the Xtalks full article to explore this fascinating topic: https://lnkd.in/eU3smFgG 🎥 Or watch the video for a quick overview: https://lnkd.in/eJQdWAQf Let's discuss how these insights could impact our approach to cancer research and treatment. Share your thoughts below! 👇 #CancerResearch #Genetics #xtalks #Eurofins

Time to pause and definitely worth the read ...an important editorial published in The Lancet #Oncology on the incorporation of whole genome sequencing into #cancer #care. The global oncology community still struggles to incorporate comprehensive genomic profiling into the management of patients with #cancer and even if there is access to testing this does not automatically guarantee access to molecularly guided therapy options. Yet, there is a call to broaden our diagnostic scope to exomes and genomes and various initiatives around the globe are venturing in this space. With allocation of sufficient resources, I do not foresee problems with feasibility (as demonstrated in the examples cited), yet the clinical value of broadening our diagnostic capacities in the genomic space (as in genomes and exomes) has not been proven to a degree of clinical applicability. The editorial states that in times of limited resources "WGS clearly adds to our knowledge of cancer biology, but more evidence is needed to assess its potential to inform cancer medicine and positively affect patient outcomes. Effective inclusion of genome sequencing into existing health systems presents a major challenge and will require careful consideration before implementation" OncoAlert 🚨 #PrecisionMedicine #PrecisionOncology Vivek Subbiah, MD raffaella casolino https://lnkd.in/dVwp6HPu

I couldn't agree more with these insightful reflections. While genomics plays a crucial role in cancer care, integrating whole genome sequencing into routine practice remains both unfeasible and questionable for many reasons. Understanding the potentials, limitations, and challenges of this technology is one of the objectives of the #LancetOncology Commission on Cancer Genomics, currently under development. Join us if you have original ideas you wish to push forward! IARC - International Agency for Research on Cancer / World Health Organization World Health Organization European Commission ICGC ARGO #Oncology #CancerOmics #TheLancetOncology

Why Men Should be Screened for the ‘Breast Cancer Gene’ https://lnkd.in/giV6h6eW New research shows that men can carry mutations in the BRCA1 and BRCA2 genes that increase their risk of several cancers, but new national guidelines are helping to educate patients. Newly developed guidelines offer hope for identifying the cancer risk of BRCA mutations in men through genetic testing and tailored cancer screening, according to an article published in JAMA Oncology. Identification of genetic risks can lead to tailored screening, finding cancers earlier and thus improve their chances for better cancer treatment outcomes. Male carriers of BRCA1/2 mutations are at higher risk of prostate, pancreatic, breast and other cancers over the course of their lifetimes. The post Why Men Should be Screened for the ‘Breast Cancer Gene’ appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

💡 NEW FINDINGS: EWSR1 is a member of the FET protein family, which contributes to RNA activity. Researchers uncovered how EWSR1 can exist in a distributed or concentrated state, a finding that adds insight into how FET proteins regulate transcription and participate in some diseases. National Cancer Institute (NCI) ➡ Read more: https://lnkd.in/ehtCEwnz This research was largely spearheaded by a team led by Dr. Natasha J. Caplen, an investigator in our Genetics Branch. Dr. Caplen and her lab members apply the perturbations induced by RNA- or DNA-based technologies to interrogate specific aspects of the genetic, transcriptional, and cell-signaling alterations observed in cancer cells. These functional genetic approaches will be used to enhance our understanding of the mechanistic basis of cancer and to discover new cancer treatment strategies.  

8 May marks World Ovarian Cancer Day. Guardant Health would like to honour all women who are fighting against ovarian cancer. As a precision oncology company, we are doing our best to ensure that no woman is left behind in her fight against cancer. Our liquid biopsy test can detect microsatellite instability-high (MSI-High) and all four classes of genomic variations in clinically relevant genes, out of which, BRCA1, BRCA2, NTRK1 fusion and MSI-High can be found in ovarian cancer. Therapies targeting these gene mutations may be available in your country. Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. #guardanthealthamea #guardanthealth #guardant360 #WorldOvarianCancerDay #WOCD2024 #NoWomanLeftBehind #PowerfulTogether #ovariancancer #liquidbiopsy #genomicprofiling

Breakthrough in Breast Cancer Risk Assessment Researchers have made a significant discovery in assessing breast cancer risk for individuals with BRCA mutations. Key findings: - Normal breast tissue can harbor hidden cancer-causing genetic mutations - These mutations can be detected through genome profiling - A new "clonality score" can evaluate cancer risk in high-risk individuals Implications: - Potential for early intervention and preventive measures - Improved breast cancer risk assessment for BRCA mutation carriers - Enhanced understanding of cancer development https://lnkd.in/gRx-jPZS

What an existing news to share! Recent scientific findings have highlighted an exciting new benefit of Vitamin D—its ability to foster the growth of beneficial gut bacteria in mice, which in turn enhances their immunity against cancer. This pivotal discovery not only extends our knowledge of Vitamin D’s extensive health benefits, which include supporting bone health and modulating immune function but also suggests its potential role in cancer prevention strategies. If I would advise someone for a better health, I would instantly mention Vitamin D 💊. #Vitamins #Cancer #Gut #Microbiota

🔍 🚨 In our recent article "Genomic Profiling of the Hallmarks of Cancer," we not only assigned genomic alterations to each hallmark but also uncovered some intriguing patterns. 🧬🧩 Through our systematic profiling, we identified certain genomic alterations that were unique to specific hallmarks. 🔬💡 This suggests that these alterations may play a crucial role in driving those particular cancer processes. 🎯 On the other hand, we also found genomic mutations that were shared across multiple hallmarks. 🔗 This highlights the complex and interconnected nature of cancer biology, with some alterations influencing various aspects of tumor progression. 🌐 By distinguishing between unique and shared genomic alterations, our approach provides a more nuanced understanding of the molecular mechanisms at play. 🔬🔍 This knowledge could help guide the development of more targeted and effective cancer therapies. 🎯💉 Read the full article to dive deeper into these fascinating findings and their potential implications for precision oncology! 📊📈 #CancerGenomics #HallmarksOfCancer #PrecisionMedicine https://lnkd.in/gz7ekgh5

A new study in Med by Cell Press looked at how often mutations occur in different genes linked to cancer, and compared this to how much research funding and how many publications focused on those genes. The authors found basically no connection. This suggests that cancer research might not be focusing on the most common mutations, and that researchers and funders might want to consider changing how they allocate resources. #cancerresearch #fundingpriorities https://lnkd.in/eBN9VdZ6